REGULATORY
MHLW Study Group Postpones Decision on Relief System for Victims of Health Damages Due to Anticancer Drugs
At a meeting on November 18, the Ministry of Health, Labor and Welfare’s (MHLW; Korosho) Study Group on the Relief of Health Damage Caused by Anticancer Drugs (chairman: Professor Emeritus Akio Morishima, Nagoya University) decided to postpone its results for…
To read the full story
REGULATORY
- LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
June 19, 2026
- MHLW Panel OKs Technical Review Group for OTC-Like Drug Charge System
June 19, 2026
- MHLW Official Warns of High Risks from GLP-1 Use in Cosmetic Weight Loss
June 19, 2026
- LDP to Launch Study Group on Lag and Loss of Pediatric Cancer Drugs
June 19, 2026
- LDP Patch League Urges Drug Price Support as Costs Continue to Climb
June 19, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





